Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CervoMed Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CRVO
Nasdaq
8731
https://cervomed.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CervoMed Inc
CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24…
- Apr 10th, 2024 10:35 am
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
- Apr 2nd, 2024 11:00 am
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Apr 1st, 2024 12:00 pm
CervoMed to Participate in Upcoming Investor Conferences
- Mar 28th, 2024 8:05 pm
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
- Mar 28th, 2024 12:30 pm
We're Not Very Worried About CervoMed's (NASDAQ:CRVO) Cash Burn Rate
- Mar 9th, 2024 12:59 pm
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
- Mar 5th, 2024 1:00 pm
CervoMed to Participate in the BIO CEO and Investor Conference
- Feb 21st, 2024 1:00 pm
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
- Feb 20th, 2024 3:22 pm
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
- Feb 12th, 2024 1:00 pm
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
- Feb 7th, 2024 1:30 pm
Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
- Feb 6th, 2024 12:00 pm
CervoMed to Participate in the Emerging Growth Conference 67
- Feb 5th, 2024 1:00 pm
Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream
- Jan 10th, 2024 12:00 pm
CervoMed to Participate in the Emerging Growth Conference 66
- Jan 5th, 2024 1:00 pm
CRVO: Publications Highlight Neflamapimod as Potential Disease-Modifying Therapy for Major Dementias…
- Nov 16th, 2023 12:37 pm
CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights
- Nov 13th, 2023 12:00 pm
CRVO: New Data from Phase 2a Trial Presented at CTAD…
- Oct 30th, 2023 3:21 pm
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies
- Oct 25th, 2023 6:50 pm
CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias
- Oct 24th, 2023 11:00 am
Scroll